A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Status:
Recruiting
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms
involved in generating and maintaining antitumor immune response will lead to a tolerable and
robust anti-tumor response. This study utilizes an innovative clinical trial design to
determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting
multiple, distinct combination regimens that modulate several immune and non-immune
mechanisms by escalating the number of therapies administered.